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Abstract
Current trends in liver disease are changing due to increased access to
pharmacotherapies and the worsening burden of obesity. Large, observational cohort
studies are a common tool in clinical and epidemiological research to determine risk for
patients that may have experienced an exposure of interest. Past studies have largely
examined risk factors for liver disease in patients with cirrhosis or fatty liver disease. We
utilized retrospective cohort studies in a disease-agnostic approach and aimed to
characterize risk for two increasingly prevalent populations: patients with severe acute
liver injury and those with liver fibrosis progressing to hepatocellular carcinoma (HCC).
First, we studied the Nationwide/National Inpatient Sample (NIS), the largest
publicly available United States all-payer inpatient database of over eight million hospital
stays, to assess for a meaningful association between weekend admissions and in-hospital
mortality for severe acute liver injury. Descriptive statistics were run for patient and
hospital factors, and complete-case univariate and multiple logistic regression modeling
of in-hospital mortality by weekend admission and other covariates was performed. Our
findings did not detect a difference in outcomes for patients hospitalized for severe acute
liver injury on weekends compared to weekdays. However, our analysis revealed that
racial differences and facility factors may be associated with worse outcomes.
Next, we analyzed the Veterans Affairs (VA) electronic health record data for all
veterans born between 1945-1965 (the “birth cohort”) to characterize risk factors for
HCC in over two million patients without viral hepatitis (hepatitis B and/or C). By
stratifying patients based on Fibrosis-4 Index (FIB-4) for liver fibrosis, we investigated
the impact of lifestyle factors on HCC risk. Bivariate analysis revealed increased HCC
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events among veterans with a low likelihood of cirrhosis (FIB-4<3.25); additionally,
ongoing smoking is a significant risk factor in this population. Multivariate analysis
revealed that male gender, age >60 years, Hispanic ethnicity, diabetes, excessive
drinking, and obesity were significantly associated with HCC, while younger age and
black race were associated with decreased HCC risk.
In conclusion, the profile of liver disease is evolving due to multiple
sociodemographic factors. Retrospective cohort studies are a useful tool to study trends in
patient outcomes and to identify potential areas to mitigate risk.
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Statement of Purpose
To conduct two retrospective cohort studies of distinct liver diseases using unique, largescale national databases.

Specific Aims
(1) To study the Nationwide/National Inpatient Sample, the largest publicly
available all-payer inpatient database in the United States, and assess for
evidence of an effect of weekend admission and other risk factors for inpatient mortality in patients hospitalized for severe acute liver injury.
(2) To investigate the Veterans Affairs Birth Cohort, a database of over three
million patients born between 1945 and 1965 from the Veterans Health
Administration’s electronic health record, to evaluate risk factors for
hepatocellular carcinoma in a veteran population without viral hepatitis.
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Chapter I: The Cohort Study in Liver Disease
1.1 The Cohort Study
Epidemiology is the study of patterns to identify determinants of disease at the
population level.2 A modern epidemiological approach to investigating exposure risks for
specific illnesses is the observational study, which follows groups with defined
characteristics to determine the incidence of and outcomes associated with disease.3 A
powerful analytic tool in epidemiology is the cohort study, in which a disease-free
population is grouped by a select exposure, and is then followed over time until the
outcome of interest occurs.4 This study design provides the data required to calculate
rates of disease in exposed and unexposed individuals, examine multiple outcomes of
rare diseases, and identify associations between potential exposure risks and outcomes.5
1.2 Prospective and Retrospective Cohort Studies
Cohort studies can be prospective, allowing researchers to preselect data to be
collected. Alternatively, they can be retrospective, allowing researchers to investigate risk
factors in patients known to have the outcome of interest.6 The unique and shared
advantages and disadvantages of both cohort study types are shown in Figure 1. Overall,
prospective cohort studies are used to answer questions about risk factors and disease
outcomes because data collection procedures are determined before disease develops in
any of the subject participants, allowing for consistent, detailed collection of baseline
information on exposures.7 Prospective cohort studies unfortunately require long latency
periods, can be expensive and time-intensive, and are vulnerable to loss of follow-up, as
exemplified by the landmark Framingham Heart Study.8 The retrospective cohort study,
which looks to the past to identify risk factors for medical outcomes, is a common study
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design that allows researchers to characterize exposure risks, control for confounding,
and make predictions about survival; such as the association of liver fibrosis with longterm mortality patients with nonalcoholic fatty liver disease (NAFLD).9 A key feature of
retrospective cohort studies is that the design is not preplanned – rather, the investigator
must review data and determine the point in time participants were exposed to a risk
factor of interest. The primary disadvantage of retrospective cohort studies is that existing
data may be inconsistent or incomplete for the exposure of interest.3 However, this
method is particularly useful in patients with a rare exposure of interest, as a database can
be investigated over a larger timeframe so that enough cases are identified to sufficiently
power a study.

Figure 1. Comparison of Prospective and Retrospective Cohort Study Designs.
Adapted from LaMorte.7
1.3 Observational Cohort Studies in Liver Disease
The landscape of liver disease is evolving in the setting of new medical therapies,
increased prevalence of hepatotoxic agents, and the worsening burden of obesity.10,11
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With mounting clinical evidence supporting the beneficial effects of lifestyle
modification and patient-centered education as the primary therapies for the management
of acute and chronic liver diseases12, large database studies of these patient populations
can validate potential risk factors in liver disease and may provide insight towards
improving the health of the general public.13 While randomized controlled trials provide
the highest level of evidence, well-designed observational studies can provide
comparable estimates of risk and are valuable tools for identifying predictive factors for
disease.14 One risk of observational studies is that cohorts defined by a common
characteristic may also share confounders that affect the outcome. However, wellplanned retrospective cohort studies can minimize the effect of confounding factors by
adjusting for multiple exposures, without having to change who is or isn’t exposed to the
risk factor of interest.15 Observational studies of adverse behaviors, such as smoking and
illicit substance use, also provide an ethical alternative to deliberately exposing
participants to harm as would be indicated in an experimental design.16
1.4 Application of Cohort Study Design to Investigate Liver Disease
We sought to conduct retrospective cohort studies of two databases to study
unique conditions of acute and chronic liver disease: the National/Nationwide Inpatient
Sample (NIS) and the Veterans Affairs (VA) Birth Cohort. The large sample sizes and
long follow-up durations for these medical records allow us to study differences (i.e.,
incidence) among those with exposures of interest compared to those who are
unexposed.3 First, we utilized a publicly accessible database available for purchase – the
National/Nationwide Inpatient Sample, to study a major cause of mortality in otherwise
healthy patients – severe acute liver injury. Our primary outcome of interest was in-
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hospital mortality attributable to severe acute liver injury. Our main exposure of interest
was weekend admission compared to weekday admission status, which has been reported
for a variety of gastrointestinal and other medically emergent conditions.17-21 An
observational cohort design allowed us to also identify patient demographic and hospitallevel risk factors associated with mortality for this cohort of severe acute liver injury
patients with in-patient hospitalizations.
We then studied another type of cohort, a birth cohort, which includes all patients
linked by their birth within a given time frame.16 Specifically, we utilized the Veterans
Affairs (VA) Birth Cohort, a detailed database of veterans born between 1945-1965 with
a high prevalence of liver cancer22 and at-risk behaviors such as smoking and drinking.23
By identifying patients with incident hepatocellular carcinoma, our outcome of interest,
we were able to study multiple exposures that may increase risk for liver cancer –
including unhealthy alcohol use, diabetes, high body mass index (BMI), and smoking.
Retrospective cohort studies allow researchers to identify potential populationscale patterns of exposure for risk factors of liver disease. These results can be used to
inform health policy, guide practice, and educate patients on factors affecting liver health.
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Chapter II: National Inpatient Study of Severe Acute Liver Injury
2.1 Etiologies of Liver Injury
Severe acute liver injury (ALI) and acute liver failure are devastating, rapidly
progressive conditions that can result in high morbidity and mortality in the absence of
prompt diagnosis and cause-specific management.24-26 Acute liver failure causes diffuse
cerebral dysfunction due to cerebral edema and elevated intracranial pressure, which can
lead to permanent neurological complications or death in otherwise healthy adults.27 The
etiologies of ALI are broad, ranging from viruses causing acute hepatitis infection to
conditions of coagulopathy in pregnancy as listed in Figure 2. Many etiologies of ALI are
potentially reversible or easily managed with prompt diagnosis. Acetaminophen toxicity,
whether by intentional or unintentional overdose, is responsible for an estimated 46% of
all acute liver failure cases in the United States (US), but lasting effects can often be
mitigated with prompt N-acetylcysteine administration.28 Severe cases of Budd-Chiari
syndrome, a rare coagulopathy causing acute liver failure by vascular congestion, require
quick intervention and are curative only by liver transplantation.29

Figure 2. Common Etiologies of Liver Injury. Illustration by author.
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2.2 The Weekend Effect
Recent studies suggest that differences in patient outcomes may be due to
underlying factors associated with weekend compared to weekday admission, a
phenomenon known as the “weekend effect.” A weekend effect has been reported in the
US and Europe for a variety of emergent conditions requiring prompt diagnosis,
acquisition of management resources, and intervention, ranging from peptic ulcer
disease-related gastrointestinal (GI) hemorrhage, GI cancers, myocardial infarction, and
stroke.17-21 Meta-analyses for all-cause weekend versus weekday mortality with subgroup
analysis by personnel staffing levels, procedure rates, times, and delays, and illness
severity, has demonstrated that weekend admision has a consistently higher relative risk
of mortality.30 There have been several predictors postulated for higher mortality rates
due to weekend admissions. For emergent cases like abdominal aortic aneurysm rupture
which require surgical intervention, transfer status on the weekends to tertiary care
centers for higher acuity management has been associated with poorer outcomes.31
Similarly, inconsistencies in access to care and acute changes in patient status that require
prompt procedural intervention have been proposed as causes for a “weekend effect”.32,33
Common etiologies of ALI similarly require efficient diagnosis and intervention,
such as antidotes for toxin-exposures or liver transplantation for acute coagulopathies.
However, there have been no previous studies assessing for potential weekend effects in
ALI hospitalizations. We hypothesized that patients hospitalized with severe ALI over
the weekend would be at higher risk for adverse outcomes compared to those admitted on
a weekday. As ALI is an acute or subacute disease necessitating prompt recognition,
subspecialty management, and consideration of transfer for advanced therapies (such as
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liver transplantation), patients admitted on weekends may receive lower-quality care.
Thus, we aimed to analyze a large, national inpatient database to investigate for possible
national trends in severe ALI hospitalizations and determine if weekend admission is
associated with increased adverse events or in-hospital mortality.
2.3 Methods
2.3.1 Nationwide/National Inpatient Sample Database
The Nationwide/National Inpatient Sample (NIS) is the largest publicly available
all-payer inpatient database in the US from the Healthcare Cost and Utilization Project
(HCUP), a Federal-State-Industry partnership (Agency for Healthcare Research and
Quality, Rockville, MD), and is available for purchase. We queried the NIS files from
2000 through 2014 to obtain deidentified patient hospitalization information. Each year
of NIS up to 2014 contains data from an estimated eight million hospital stays from over
1,000 hospitals in 35 states, which corresponds to an approximate 20% state-stratified
sample of US community hospitals. NIS years after 2014 were redesigned as a sample of
discharges from all hospitals participating in HCUP, and thus were excluded from our
study. This database contains individual hospitalizations as the unit of observation and
includes sociodemographic (sex, race, income, and insurance status), clinical (length of
stay, up to 25 diagnostic codes), and patient-level outcomes data (mortality, liver
transplant status, and hospital transfer status). The NIS also contains facility factors such
as teaching status, region and urban/rural location, and hospital bed size. We were
adherent to the HCUP formal data use agreement guidelines.
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2.3.2 Patient Confidentiality and Institutional Board Review
The NIS does not provide identifiers linking hospitalizations to individuals to
protect patient confidentiality, so it was not feasible to obtain individual patient consent
for this analysis. The Yale School of Medicine (New Haven, CT) Institutional Review
Board deemed that this public, de-identified database study met criteria for exemption.
2.3.3 Study Design
We defined severe ALI patient hospitalizations as events with diagnostic codes of
acute and subacute necrosis of liver (570) with encephalopathy (572.2) in accordance
with the International Classification of Disease, Clinical Modification, 9th revision (ICDCM-9) that were used between the target years of 2000 through 2014. For all patient
hospitalizations with severe ALI, we then extracted weekend admission status data, as
well as sociodemographic and clinical characteristics that may have otherwise
confounded the effect of weekend admission on mortality. These included age, sex,
race/ethnicity (white, black, asian, Hispanic, Native American, other), income quartile,
and insurance payer (Medicare, Medicaid, private, other).
We also studied liver-related characteristics that may also affect mortality rates,
such as liver disease etiology, if known, and liver transplantation status. Comorbidity
burden was quantified through calculation of the Elixhauser Comorbidity
Index.34 Hospital-related characteristics studied were geographic region (Northeast,
Midwest, South, West) and teaching status (rural, urban nonteaching, urban teaching).
We assessed weekend day admission as the primary exposure of interest, in-hospital
mortality as the primary outcome of interest, and length of stay as a secondary outcome –
which were all available as NIS data elements.
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2.3.4 Statistical Analysis

14

Descriptive statistics on patient hospitalizations and hospital characteristics were
extracted. Normality of continuous variables (age) was assessed based on histogram
distributions. Statistical differences between groups was determined by Student’s t-test
(normally distributed variables), Kruskal-Wallis test (non-normally-distributed variables)
and chi-square tests (categorical variables), as appropriate. We subsequently performed
complete-case univariable and multiple logistic regression modeling of in-hospital
mortality by weekend admission and other covariates. All studied covariates were
included in the final model (full-model approach) with the exception of patient transfer
status, which was only available in the 2008 to 2014 datasets. To account for bias due to
confounding by missing data or patient transfer status, we conducted additional
sensitivity analyses by producing separate multiple regression models which also
included: (a) patient transfer data (indicator for patients transferred in from another health
facility) to account for potential confounding, and (b) 10 multiple imputation datasets to
account for missing covariate data. All analyses were performed in Stata 14.2 (College
Station, TX, USA); multiple imputation was done via the MI command utilizing fully
conditional specification as to not require assumption of multivariate normal
distribution.35 Statistical significance was defined as a two-tailed p<0.05.
2.3.5 Statement of Work
Primary data extraction, descriptive statistics, multiple logistic regression
modeling, and thesis writing was done by this author. Conceptualization, methodology,
additional sensitivity analyses, and multiple imputation was performed by Albert Do,
MD, MPH. Tamar H. Taddei, MD, provided project oversight and guidance.
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2.4 Results
2.4.1 Sample Characteristics
From 2000 to 2014, 15,762 hospitalizations met the inclusion criteria and 12,182
(77.3%) had complete data. Of the 3,580 hospitalizations with missing data, 3,151
(88.0%) were missing data on at least one covariate. In the overall sample, 53.3% were
males, 69.3% were white, and the average age was 55.0 ± 14.1 years. Weekend
admissions were observed in 3,732 (23.7%) hospitalizations as listed in Table 1.
2.4.2 Descriptive Data
Table 1 demonstrates that demographic characteristics (race, income quartile,
insurance type) for severe ALI hospitalizations were similar regardless of weekend or
weekday status. In patient care, there were no significant differences in liver transplant
status or palliative care consultations. However, there was a statistically significant
difference in age among hospitalizations with weekend admissions (54.4 vs 55.1 years, ttest p=0.008) and a slightly higher proportion of hospitalizations occurred at large
hospitals (68.2% vs 66.1%, chi-square p=0.005). In-hospital mortality was not
significantly different between groups (42.3% weekday vs 42.9% weekend, chi-square
p=0.53). Median length of hospital stay was marginally shorter for weekend compared to
weekday admissions (8 vs. 9 days, respectively; Kruskal-Wallis p=0.0002).
We additionally evaluated the 3,580 patients with any missing covariate data.
Patients excluded from the analysis were similar to those with complete data in terms of
percentage of weekend admissions (24.0 vs 23.6%), mortality rate (43.0 vs 42.6%),
female sex (47.5 vs 46.5%), ALI etiology, and proportion receiving liver transplantation
(2.5 vs 2.1%) compared with included patients, respectively (p>0.05). However,
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statistically significant differences were noted between excluded and included patients in
age (53.6 vs 55.4 years), race (66. 7 vs 69.6 white race), income quartiles (30.1 vs 28.6%
first quartile), insurance provider (30.1 vs 28.6% Medicare), Elixhauser comorbidity
index (median 4 vs 5), hospital region (32.9 vs 17.3% Midwest), and hospital teaching
status (10.0 urban vs 6.8% rural), respectively (p<0.001). Additionally, length of stay was
shorter in excluded patients (median 8 vs 9 days; Kruskal-Wallis p=0.01).

Table 1. Characteristics of 15,762 Nationwide/National Inpatient Sample Patients
with Severe Acute Liver Injury, Stratified by Admission Day. As published.1
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2.4.3 Multiple Logistic Regression and Sensitivity Analysis
Table 2 shows the final multiple logistic regression model including all
covariates, in which weekend admission was not significantly associated with higher
mortality (OR [95% CI] = 1.1 [0.9-1.2], p=0.22). However, older age (1.02 per year
[1.01-1.02], p<0.001), male sex (1.1 [1.1-1.2], p<0.001), and black race or Hispanic
ethnicity (1.3 [1.1-1.5] and 1.2 [1.1-1.3], respectively; p<0.001) were significantly
associated with mortality. In-hospital mortality odds by toxin-induced liver injury was
significantly better than viral hepatitis-related liver injury (0.4 [0.3-0.7], p<0.001).
Patients with a higher comorbidity index (0.97 [0.95-0.99], p<0.001) and liver
transplantation (0.3 [0.2-0.4], p<0.001) had significantly better outcomes. Placement of
palliative care consult had a strong association with in-hospital mortality compared to
hospitalizations without a palliative care consult (3.6 [3.2-4.1], p<0.001).
Regarding hospital-level characteristics, Midwest and South geographic region
compared with Northeast hospital location were associated with better mortality
outcomes (0.85 [0.75-0.97] and 0.86 [0.78-0.96], respectively; p=0.02). Additionally,
large hospital size (1.4 [1.3-1.6], p<0.001) and urban (nonteaching and teaching) hospital
status was associated with higher in-hospital mortality compared with rural hospitals (1.5
[1.3-1.8] and 1.8 [1.5-2.1], respectively; p <0.001).
Sensitivity analysis including hospital transfer among facility covariates did not
yield statistically significant association between weekend admission and mortality (1.1
[0.9-1.2], p=0.34). A similar result was obtained with a pooled analysis using ten
multiply-imputed datasets (1.0 [0.9-1.1], p=0.35).
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Table 2. Multiple Logistic Regression of In-Hospital Mortality for 15,762
Nationwide/National Inpatient Sample Patients with Severe Acute Liver Injury.
As published.1
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2.5 Discussion
2.5.1 No Mortality Differences Associated with Weekend Admission
Of the 15,762 severe ALI hospitalizations identified from 2000 to 2014, 23.7%
(n=3,732) admissions occurred on the weekend. There were small, statistically significant
differences between admission groups in age and hospital size which were likely due to
comparing larger weekday sample size to smaller weekend admission sample sizes.
However, there were no other clinical differences observed between weekend and
weekday hospital admissions. Multiple logistic regression modeling revealed no mortality
differences associated with weekend admission. These findings persisted after statistical
covariate control, sensitivity analyses including patient transfer covariates, and multiple
imputation to account for missing data.
2.5.2 Variable Presentation of Severe Acute Liver Injury
There are several potential explanations for these results. Severe ALI can often
present variably over days or even months, unlike previously reported cases of observed
weekend effect for myocardial infarction, GI hemorrhage, or stroke. All previously
documented incidences of weekend effect involve scenarios of immediate, lifethreatening events necessitating a well-defined, short time course to intervention to
prevent morbidity and mortality. An exception to this could be observed in less-common,
severe ALI presentation of hyperacute liver failure (onset <7 days).36 However, our deidentified database is unable to stratify hospitalization diagnosis by time course of illness.
Otherwise, severe ALI cases like toxic ingestion or coagulopathies may evolve over a
protracted time course, with antecedent symptoms up to 12 to 24 weeks before
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presentation.24 This prolonged disease progression may be why there are no detectable
differences in mortality for patients admitted over the weekend compared to weekdays.
There are also differences in utilization of resources for severe ALI that may not
depend on weekday availability. For example, acute GI bleeding requires emergent
intervention such as endoscopy, which not only necessitates additional equipment, but
also additional technicians or nursing staff that may be more difficult to assemble over
the weekend. Except for liver transplantation, which occurs in a minority of patients with
liver injury, the management of severe ALI is primarily medical. Specific therapies
include antiviral drugs for viral hepatitis, steroids and other adjunctive therapies for
autoimmune and alcoholic hepatitis, activated charcoal and N-acetylcysteine for
acetaminophen-induced hepatitis, and prompt removal or reversal of any offending agents
in drug-induced liver injury25. These methods for medical management are generally
achievable in any hospital with trained staff, with some antidotes even more readily
available in the emergency department setting for common toxic ingestions. However,
procedural and surgical interventions often require more time and effort to assemble
additional specialized staff, equipment, and facilities for emergent conditions. An
illustrative example is acute gallstone pancreatitis, for which patients admitted on the
weekend were found to experience greater delays in getting an endoscopic retrograde
cholangiopancreatography (ERCP), with prolonged hospital stay and increased overall
cost.37 For severe ALI, the wide availability of medical therapies regardless of day of the
week may be a possible explanation for why length of stay did not largely differ.
In patients with severe ALI, the Acute Liver Failure Study Group reported that
full recoveries were the primary clinical outcome in 93% of cases.26 However, our
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observed sample survival group was considerably lower at 58%. The higher mortality
rate observed in our study may signify that an our inclusion criteria failed to capture a
broader definition of acute liver failure patients, which lead to a smaller sample
denominator and subsequently lower survival group. Alternatively, this difference may be
due to our more selective acquisition of patients with greater illness severity based on the
combined diagnosis codes used to define severe ALI, as not all patients with liver injury
may develop frank encephalopathy that would yield additional diagnosis on
hospitalization records beyond suspected liver necrosis. Our diagnostic codes also allow
for the inclusion of patients who progress to acute liver failure, further decreasing
survival outcomes. Thus, our study could be a more accurate observation of worse
survival outcomes given a more strigent ICD composite definition for severe acute liver
injury patients.
2.5.3 Risk Factors for In-Hospital Mortality for Severe Acute Liver Injury
Multiple regression analysis revealed significant patient and hospital-level
characteristics that were associated with greater mortality. Compared with white
populations, black patients had increased odds of in-hospital mortality for hospitalization
with severe ALI. There are multiple potential genetic and sociodemographic explanations
for racial disparities in hospital outcomes, particularly for chronic liver diseases such as
nonalcoholic fatty liver disease.38 However, our findings suggest that further
investigation into racial disparities for more acute liver conditions, such as severe ALI,
may reveal trends in hospitalization outcomes not previously studied.
Our analysis also revealed that urban location and large hospital status were
associated with higher mortality. Previous studies have attributed this difference in
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hospital outcomes to the possibility that sicker patients are transferred to larger referral
centers for specialized care, and ultimately may have higher mortality rates upon
admission to the higher care center.31 However, we incorporated transfer indicator
variables and controlled for comorbidity burden with the Elixhauser Comorbidity Index
in our subgroup analysis. Additionally, our study found that those with higher
comorbidity index and liver transplantation had better outcomes, which may be expected
for sicker patients who warrant more urgent care and ultimately receive curative
treatment. Our results did not significantly alter the findings of the multivariate
regression model, perhaps indicating that patients with severe ALI are primarily sent to
larger hospitals rather than escalated from smaller hospital care. This suggests that there
may be other factors not captured by the patient sociodemographic and hospital-level
factors in the NIS database, such as availability of liver-specific therapies (such as liver
transplantation) and medical staffing continuity of care.
2.5.4 Limitations
There are some notable limitations to our study. The composite severe ALI
case definition drawn from diagnostic codes is not as definitive as patient-provider level
data including historical, clinical, and laboratory criteria.39 Because there is no validated,
high-performance definition for severe ALI or failure with diagnostic codes, this study is
limited by the possibility of disease misclassification. However, we were careful to avoid
labeling this sample as having acute liver failure, as we were unable to determine whether
a given patient had chronic liver disease antecedent to hospitalization. We recognize that
our analysis likely does include patients with acute liver failure, recognizing it as the
severe phenotype of ALI or progression of severe ALI. In a study of diagnosis code
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performance in acute liver failure, Lo Re and colleagues found a positive predictive value
of 67% using a combination of diagnosis codes; however, this only identified 3% of acute
liver failure cases.40 Furthermore, the NIS database only reports on hospitalization-level
data and does not account for multiple hospitalizations by the same individual, although
this would be a larger concern with rarer diseases with smaller sample sizes. We did not
perform statistical analysis using statistical weights or survey-based analytical methods,
as this study did not explore nationwide or temporal trends. Due to our focus on inhospital mortality and length of stay as outcomes of interest, we are not able to make
observations on other important clinical outcomes. Previous studies have identified druginduced or acetaminophen-induced liver injury as the most common culprits for ALF, and
we suspect low ascertainment of this etiology, as toxic exposures may not be evident or
documented as a diagnosis code during hospitalization.41
2.5.5 Conclusion
Despite previous studies describing mortality differences in other emergent
medical conditions, we observed no evidence of a weekend effect on mortality in
hospitalizations for severe ALI in an analysis of a large, national inpatient database.
However, we found that mortality was associated with older age, male sex, black race,
Hispanic ethnicity, and viral-induced hepatic disease, which warrants further study.
Additionally, our analysis revealed that hospital-level characteristics may impact
outcomes of severe ALI hospitalizations, with higher mortality in larger, urban teaching
hospitals and in the Northeast region of the United States. Ultimately, further studies are
also needed to address potential bias in hospital care and improve resource allocation for
inpatient treatment of acute hepatic emergencies, irrespective of admission day.
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Chapter III: Lessons Learned from Conducting a Public Database Analysis
3.1 Public Healthcare Database Reflection
Healthcare databases can be used to provide evidence of outcomes associated
with disease with greater confidence in reproducible results given clear parameters to
facilitate assessment of validity.42 This study of the Nationwide/National Inpatient
Sample benefits from several strengths, ranging from use of ICD diagnostic codes to
clearly-defined analysis parameters performed on widely standardized public data for
potential reproducibility and further study collaboration. Utilization of composite
diagnosis codes for severe acute liver injury reflects higher likelihoods of ascertainment
of the correct target patient population. Simplicity in defining admission day, statistical
control for multiple patient- and hospital-level characteristics, and unchanged results
when including transfer status and multiple imputation datasets all contribute towards
reducing bias, thus strengthening study validity. The clearly defined variable definitions
and datasets available in these studies allows for answering specific questions regarding
acute disease, such as differences in acute liver injury hospitalizations based on
admission day, as well as assessment of large general trends in specific patient subpopulations.
Public databases allow researchers of all levels to access large, variable cohorts
and pursue clinically-relevant questions from a variety of medical fields and perspectives.
Ultimately, large database studies like ones drawn from the NIS allow for reproducible
analyses for assessing trends in well-defined populations given concrete variable
definitions. For researchers with limited access to protected healthcare information or
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seeking population-level research questions that do not require granular details such as
follow-up visit data, public databases are a valuable epidemiological resource.
3.2 Limitations of Public Database Study
There are some limitations to public database studies. In public access, deidentified databases such as the National/Nationwide Inpatient Sample, there is no way to
assess granular level exposure risks that may affect liver disease risk or mitigate fibrosis
progression, such as medication exposures.43-48 We were also limited by the availability
of data related to our outcome of interest. For example, although our goal was to
investigate the impact of transfer status on in-patient hospitalizations for severe acute
liver injury, patient transfer status was not available in this database prior to 2008.
As liver injury is a composite variable created by combining hepatic
encephalopathy and hepatic necrosis, another limitation is potential misclassification of
liver injury severity by providers. For example, the most common etiology of severe
acute liver injury is acetaminophen ingestion, for which a hospitalization can be coded as
a possible suicide attempt or hepatic necrosis secondary to toxic ingestion. Standardizing
the reporting of emergent conditions into a distinct diagnostic code may yield better
acquisition and a subsequently more robust analysis.
A major advantage of utilizing large public healthcare databases is that their
results can be used to identify general trends in disease or develop algorithms to predict
risk. However, public databases will never be able to predict individual patient outcomes
and are often limited in their ability to produce widely generalizable results. Additionally,
observational studies of public databases can infer associations between risk factors and
diseases but not definitively capture causation as in randomized control trials. It is the
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responsibility of epidemiologists and clinicians alike to report these trends, but
researchers and providers should also caution patients that trends observed at the
population-level do not necessarily translate into individual patient experiences.
3.3 Planning the Next Database Study
Due to the lack of control with variables available in this public database, I sought
a database where I would be able to define study parameters and conduct a more rigorous
analysis. I took the principles learned from this public database study and utilized a
private access database to investigate a major topic in liver disease – hepatocelluar
carcinoma. With greater methodical planning, I learned how to craft more definitive
parameters for data extraction, studied more sophisticated coding and analysis
techniques, and broadened my foundational knowledge of clinical epidemiology.
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Chapter IV: Birth Cohort Study of Hepatocellular Carcinoma Risk Factors
4.1 Hepatocellular Carcinoma Risk
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
and its global incidence is steadily increasing.49 Due to the growing prevalence of obesity
and increased utilization of direct-acting antiviral (DAA) therapies, chronic hepatitis C
(HCV) infection is no longer the most common etiology of HCC.50,51 Previous studies
assessed HCC risk factors in liver disease-specific cohorts, including cirrhosis, alcoholrelated disease, HCV, or non-alcoholic fatty liver disease (NAFLD).52-54 However, the
incidence of HCC and its associated risk factors in a population without viral hepatitis is
unclear.
In this study, we sought to identify clinical variables that influence HCC-risk in a
veteran population without viral hepatitis. We investigated both modifiable risk factors
(diabetes, smoking, alcohol use, and obesity) and non-modifiable risk factors
(demographic factors and hepatic decompensation) for HCC in patients without HCV or
hepatitis B (HBV) using the Veterans Affairs (VA) Birth Cohort. We stratified our
population using a validated, commonly used clinical practice measurement of liver
fibrosis likelihood (FIB-4)55-57 and evaluated how modifiable factors alter HCC risk.
4.2 Methods
4.2.1 Veterans Affairs Birth Cohort Database and Institutional Review Board
The VA is the largest integrated health-care system in the United States (US)
consisting of 152 VA Medical Centers and 1,400 community-based outpatient clinics. All
routine clinical data, HCV treatment history, and complete mortality data are accessible
through an electronic medical record system.58,59 This study utilized the Birth Cohort,
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which includes veterans born between 1945 and 1965. Deaths are identified from the VA
Vital Status file, which uses data from the Social Security Death Master File, Medicare
Vital Status Files, and VA Beneficiary Identification and Records Locator Subsystem.
Institutional review board approval was obtained prior to data collection.
4.2.2 Patient Selection, Outcomes, and Covariates
A flowchart including the inclusion and exclusion criteria used to establish the
study population is presented in Figure 3. This study included patients receiving VA care
from September 30, 2007, the national VA implementation date of reported alcohol
consumption screening for excessive drinking (AUDIT-C), through September 30, 2017,
the last entry date for the Birth Cohort. The first primary care visit with an AUDIT-C
score was used as the index date. To evaluate HCC status and create a naïve cohort, we
established an observational window defined as 12 months prior to and 6 months after the
index date. Patient were excluded if they were missing primary care data (AUDIT-C
score, body mass index (BMI), FIB-4 score, smoking status), died within the
observational window, or had a history of HBV or HCV as determined by laboratory
testing [i.e., any positive HCV lab, (HCV antibody, or HCV RNA qualitative or
quantitative)] or International Statistical Classification of Diseases and Related Health
Problems (ICD) codes. Incident HCC was determined by ICD-10 topography code C22.0
(liver) and morphology codes 8170-8180 (HCC) from the International Classification of
Diseases for Oncology, Third Edition (ICD-O-3), consistent with Surveillance,
Epidemiology, and End Results (SEER) algorithm.60
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Figure 3. Design of National Study of VA Birth Cohort Patients In Care
Between September 2007 and 2017.
The following clinical demographic data was collected: age, gender,
race/ethnicity, liver disease severity (hepatic decompensation), lifestyle modification risk
factors (smoking, alcohol use, diabetes, BMI), and FIB-4 score (derived from age,
platelet count, and liver enzyme labs). Hepatic decompensation was determined using
ICD codes and FIB-4 values. Smoking status was ascertained using VA Health Factor
data file and categorized as never, current, or past smoker. Alcohol use was based on
AUDIT-C and alcohol use disorder (AUD) ICD codes. Diabetes status was based on labs,
ICD codes, and medications. Continuous variables were discretely categorized as
follows: Age:<50, 50-54, 55-59, and >60; BMI (kg/m2): <20, 20-24, 25-29, 30-34, 35-39,
40-44, and >45. Alcohol use was categorized as AUDIT-C 1-3, 4, 5-6, 7-9, >9, and AUD.
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Categorical values included race/ethnicity (black, white, Hispanic, and other). Standard
FIB-4 categories are: FIB-4 <1.45 (94.7% negative predictive value to exclude severe
fibrosis with high sensitivity), FIB-4 1.45-3.25 (moderate fibrosis risk), and FIB-4 >3.25
(82.1% positive predictive value to confirm the presence of significant fibrosis with high
specificity).55-57 All cutoffs were selected based on previously validated thresholds or a
consensus reached among the team based on best available evidence. Definitions for risk
factor variables used in analyses are listed in Table 3.

Table 3. Definitions for Risk Factor Variables Used in Cohort Study.
4.2.3 Statistical Analysis
We performed descriptive analyses and estimated the incidence rates of HCC
(events per 1,000 person-years). Multivariate Cox regression models were used to
calculate hazard ratios (HRs) and 95% CIs, and all statistically significant predictors were
used to adjust the base multivariate model, with the impact of these effects estimated
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using the chi-squared test. Subsequently, we ran stratified models by FIB-4 category,
<1.45, 1.45 – 3.25, >3.25. A sub-analysis excluding patients with diabetes was performed
to evaluate if HCC risk was similar in magnitude and direction to the general cohort as
outlined in Tables S2-S4. Patients with missing variables were studied to confirm their
magnitude and direction of risk was similar to the studied group prior to exclusion.
Analyses were done using SAS, version 9.4 (SAS Institute). Statistical significance was
defined as a two-tailed p <0.05.
4.2.4 Statement of Work
Descriptive statistics, univariate and multivariate analyses, sub-analyses, and
primary manuscript writing was done by this author. Primary variable extraction was
performed by Supriya Krishnan, ScD and Kirsha S. Gordon, PhD. Statistical support was
provided by Kirsha S. Gordon, PhD and Janet Tate, MPH, ScD. Amy C. Justice, MD,
PhD, and Tamar H. Taddei, MD, provided project oversight, guidance, and feedback.
4.3 Results
4.3.1 Baseline Characteristics and Hepatocellular Carcinoma Incidence
Baseline characteristics of the study participants are in Table 4. The 2,107,169
veterans without viral hepatitis were 31.2% nonwhite, 48.7% age >60 years old, and
50.7% obese (BMI >30kg/m2) at their baseline visit. Medical comorbidities included
history of diabetes (23.3%), history of hepatic decompensation (0.1%), AUD (43.7%),
and AUDIT-C screening score of 4 or greater (18.9%). The breakdown of baseline FIB-4
scores is as follows: FIB-4 <1.45: 71%, FIB-4 1.45-3.25: 27.3%, and FIB-4 >3.25: 1.9%.
Of the 1,345 HCC incident cases, 59.3% of patients had a baseline FIB-4 <3.25 (n=797),
consisting of 19.2% with FIB-4 <1.45 (n=258) and 40.1% with FIB-4 1.45-3.25 (n=539).
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HCC incidence overall was 219.3 per 1,000 person-years (PY) and shown for
each baseline characteristic in Table 4. HCC incidence was higher in non-whites and
those with FIB-4 >3.25. Patients with BMI <20 kg/m2 (553.8/1,000 PY) and history of
hepatic decompensation (340.3/1,000 PY) had the highest incidence rates. Smokers and
non-smokers had comparable incidence. AUD had the highest incidence for modifiable
risk factors (271.2/1,000 PY).

Table 4. Baseline Characteristics of the 2,107,169 VA Birth Cohort Patients
Without Viral Hepatitis.
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4.3.2 Multivariate Modeling Results
Univariate analysis revealed elevated HCC risk with male gender, Hispanic
ethnicity, diabetes, hepatic decompensation, smoking, unhealthy drinking, and increasing
BMI. Multivariate modeling was then conducted, controlling for demographic factors,
history of diabetes or hepatic decompensation, and lifestyle risk factors (smoking,
unhealthy alcohol use [AUDIT-C and/or AUD], and BMI) as shown in Table 5.
Multivariate analysis showed that males had an adjusted hazard ratio of 2.7, indicating a
2.7-fold increased probability of developing HCC compared to females (95% CI = 1.6 to
4.6, p<0.001). Hispanic ethnicity had 2.0-fold increased likelihood of HCC (1.7 to 2.4,
p<0.001), while black race had 0.5-fold decreased rate compared to white race (0.4 to 0.6,
p<0.001). Diabetes had a 2.5-fold increased probability of HCC (2.2 to 2.8, p<0.001).
Current smoking had 1.6-times the rate of HCC compared to never-smokers (1.42 to
1.88, p<0.001).
The greatest predictors of HCC were hepatic decompensation (HR [95% CI] =
5.1-fold risk [4.0 to 6.7], p<0.001) and FIB-4 >3.25 compared to <1.45 with (72.8-fold
risk [62.3 to 85.1], p<0.001). Excessive drinking represented by AUDIT-C >4 or positive
AUD diagnosis had increased relative risk compared to low-moderate alcohol use
patients (AUDIT-C 1-3 without AUD diagnosis). Increasing BMI had a dose-dependent
increased HCC probability. Multivariate analysis revealed that overweight BMI category
of 25-29 kg/m2 was associated with increased HCC likelihood not initially evident by
univariate analysis, (1.3-fold risk [1.1 to 1.6], p=0.01).
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Table 5. Independent Predictors of Hepatocellular Carcinoma Compared to
Multivariate Analysis For 2,107,169 VA Birth Cohort Patients Without Viral Hepatitis.
4.3.3 FIB-4 Stratification of Hepatocellular Carcinoma Risk Factors
Across all three FIB-4 stratifications, significant demographic risk factors for
HCC included greater than two-fold increased likelihood for male gender, dosedependent increase with older age, decreased relative risk with black race compared to

Acute and Chronic Liver Disease: Lessons Learned from Retrospective Cohort Studies | #33

white. Among patients with FIB-4 <3.25, Hispanic ethnicity had almost doubled HCC
probability. History of diabetes had a three-fold increased HCC likelihood in patients
with FIB-4 <3.25, compared to only 1.8-times relative risk in patients with FIB-4 >3.25.
History of hepatic decompensation was associated with the greatest magnitude of HCC
likelihood in patients with greater fibrosis (FIB-4 1.45-3.25: (16.4-fold [9.1 to 29.5] and
FIB-4 >3.25: 4.5-fold [3.4 to 6.0]).

Figure 4. FIB-4 Stratification of Hepatocellular Carcinoma Risk Factors.
Illustration by author.
The FIB-4 stratified models in Table 6 also demonstrate that current smoking
status had an increased HCC probability compared to never-smokers with low and
moderate FIB-4, an effect which was lost in the high FIB-4 category. Excessive drinking
showed a dose-dependent trend in HCC risk that was greater in magnitude in patients
with FIB-4 <3.25 with increasing AUDIT-C score, and a positive diagnosis of AUD
conferred a two-fold increased HCC likelihood. Increasing obesity had a dose-dependent
increase in HCC probability across all FIB-4 levels.

Table 6. Side-By-Side Multivariate Analysis of the 2,107,169 VA Birth Cohort Patients Without Viral Hepatitis,
Stratified by FIB-4 Status.
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4.3.4 Baseline Characteristics of Patients Without Diabetes
Baseline characteristics of the subgroup of patients without diabetes are in Table
7. Of the general cohort, 76.7% of patients did not have diabetes. Of this subgroup,
0.04% had HCC (n=643) with similar demographic distributions to the general cohort –
male, age >50, white, and BMI >25. HCC incidence was higher with harmful alcohol use,
both high and low extremes of BMI, and FIB-4 >3.25.

Table 7. Baseline Characteristics and Bivariate Analysis of the 1,615,512
VA Birth Cohort Patients Without Viral Hepatitis or Diabetes.
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4.3.5 Multivariate Analysis of Non-Diabetes Subgroup
In patients without diabetes, multivariate modeling revealed that the magnitude of
HCC risk associated with male gender and obesity-level BMI categories was greater than
in the general cohort. Race/ethnicity, history of hepatic decompensation, smoking status,
and increasing FIB-4 status had similar effects degrees of HCC risk in the non-diabetic
patients. Higher BMI category was also associated with an increased risk of incident
HCC in a dose-dependent manner as shown in Table 8. Using a FIB-4 stratified model
shown in Table 9, there were more total HCC events in FIB-4 <3.25 (n=366) compared to
FIB-4 >3.25 (n=277). In patients without diabetes, HCC risk persisted with a dosedependent increase in risk with unhealthy alcohol use and increasing BMI.

Table 8. Univariate and Multivariate Analysis of the 1,615,512 VA Birth Cohort
Patients Without Viral Hepatitis or Diabetes.

Table 9. Side-By-Side Multivariate Analysis of the 1,615,512 VA Birth Cohort Patients Without Viral Hepatitis or
Diabetes, Stratified by FIB-4 Status.
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4.4 Discussion
4.4.1 Hepatocellular Carcinoma
The incidence of hepatocellular carcinoma (HCC) has tripled over the last four
decades in the US.61 Our study of over 2 million Birth Cohort veterans without hepatitis
B or C infection found that there were more HCC events in patients with FIB-4 <3.25, a
level associated with a lower likelihood of advanced fibrosis in both HCV-infected and
biopsy-proven NAFLD patients.62,63 In this population, we demonstrated that diabetes,
excessive drinking, current smoking, and obesity were significantly associated with
increased HCC risk. This association was present even after adjusting for demographic
risk factors and other metabolic and lifestyle comorbidities, and again in a subgroup
analysis of non-diabetic patients.
4.4.2 Hepatocellular Carcinoma Risk Persists
Our study revealed that obesity and diabetes are significant risk factors for HCC
in patients without HCV or HBV infection, even when accounting for liver fibrosis.
Several studies have concluded that eradication of HCV with antiviral therapy reduces
the risk of HCC,64 but disease may still occur, and the risk in those without chronic
hepatitis C has not been well-characterized. Obesity and diabetes are known independent
risk factors of HCC and contribute to the development of NAFLD with concurrent
HCC.65,66 Additionally, non-modifiable demographic factors such as race and ethnicity
have been shown to affect HCC risk. The significantly increased risk of HCC associated
with Hispanic ethnicity and the decreased risk associated with black race may be due to
genetic factors such as polymorphisms in the patatine-like phosphatase in domain 3
(PNPLA3) gene.67 Our findings also confirm that HCC risk is high in older white males,
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corroborating results from previous studies demonstrating increased HCC incidence after
age-adjustments in men of white race and Hispanic ethnicity born in the peak era of
hepatitis C virus infection.67,68
4.4.3 Modifiable Risk Factors for Hepatocellular Carcinoma
With the downtrend in viral etiologies of chronic liver disease, alcohol and
obesity have emerged as the primary drivers of hepatocellular cancer, and both are
believed to cause hepatic injury through chronic inflammation and cellular stress.69 Our
study found that unhealthy alcohol use, even in patients without advanced fibrosis, is a
strong HCC risk factor in patients who are HBV and HCV-uninfected. Additionally,
obesity and diabetes were persistent HCC risk factors, regardless of FIB-4.
The HCC risk connected to metabolic factors has likely been underestimated, and
the burden of NAFLD-associated HCC and cirrhosis is expected to worsen globally due
to the epidemic of obesity and type 2 diabetes.70,71 Our study found a dose-dependent
increase in HCC risk with increasing BMI, even among patients with low likelihood of
liver fibrosis. Many mechanisms connecting obesity, fatty liver, and cirrhosis have been
proposed, from chronic inflammation due to changes in gut microbiota in obesityassociated HCC, to correlations between childhood obesity and adult liver cancer.72,73
Recent studies have also investigated the effect of metabolic traits on increasing risk of
cirrhosis and HCC in NAFLD patients.74 In our cohort, managing diabetes through diet
and exercise may decrease HCC risk, particularly in those with early fibrosis.
Diet not only impacts weight and BMI, it can improve diabetes-related
outcomes.12 Insulin resistance is a known driver of fibrosis progression and has been
linked to increased HCC risk in patients with non-cirrhotic chronic hepatitis C.75 The
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persistence of diabetes as a HCC risk factor in our analysis, even in patients with FIB-4
<3.25, suggests an underlying mechanism related to insulin resistance may contribute to
hepatic injury in early stages of fibrosis. The hepatotoxic effects of diabetes have been
attributed to the disruption of key biological pathways such as fatty acid metabolism, as
well as elevations in inflammatory factors, which are exacerbated by hyperglycemia and
hyperinsulinemia, and lead to oxidative stress and fibrosis.76 Greater adherence to a type
2 diabetes prevention diet has been associated with a lower rate of HCC among American
men and women.77 There is also a significant multiplicative interaction between diabetes
and smoking on HCC mortality.78 Though cigarette smoking is known to increase HCC
incidence and related mortality79, our study demonstrated that the effect of current
smoking loses significance in patients with FIB >3.25, which suggests that the risk
associated with smoking is vastly overshadowed by severe fibrosis. Thus, the potential
impact of smoking cessation in reducing HCC risk in patients with low FIB-4 scores
should not be underestimated.
4.4.4 Limitations
This study has some limitations. The veteran population predominantly consists
of older white males, and though this is a population historically at high risk for
developing HCC, it is not generalizable to the larger population.67 Second, non-invasive
scoring systems have been shown to be less accurate in predicting cirrhosis and liverrelated outcomes, particularly in patients with NAFLD and diabetes.80 Though higher
scores from non-invasive fibrosis scoring systems like FIB-4 are associated with
increased cirrhosis risk in a general population, their predictive ability has better
performance in patients with shorter follow-up periods and higher baseline risk of
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NAFLD.81 FIB-4 index cutoff points for determining advanced fibrosis can also fluctuate
and have been shown to increase with age in NAFLD patients.82 Noninvasive liver
fibrosis prediction methods like liver stiffness measurements may better predict HCC
than FIB-4 scores, though studies have largely been limited to focused patient subgroups,
like those with chronic HBV.83 Additionally, our FIB-4 categorization was drawn from
first AUDIT-C score dates, but previous studies in NAFLD patients showed that FIB-4
indexes can change over time.84 However, studies in NAFLD-related fibrosis have
validated the diagnostic accuracy of the 3.25 FIB-4 value cut-off and that HCC risk
persists for up to a decade in those with high FIB-4.85-88 Therefore, we believe that FIB-4
remains a valuable, inexpensive tool to help predict HCC risk in veteran populations. As
the incidence of HCC continues to rise in tandem with the growing burden of obesity,
simple, efficient algorithms that can stratify patients by predicted risk will continue to
remain an important component of population risk prediction models and provide
guidance for individualized care.
4.4.5 Conclusion
Our retrospective study of over 2 million patients without HBV or HCV revealed
that HCC occurs more often among FIB-4 <3.25 non-cirrhotic veterans, which is a large
proportion of the Birth Cohort. In those with low likelihood of fibrosis, smoking
cessation may decrease HCC risk before the debilitating effects of permanent hepatic
scarring. While there are non-modifiable factors that predispose certain populations to
increased HCC risk such as Hispanic ethnicity, there is still valuable counseling that can
be done to improve liver health in the general population. Our multivariate modelling
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controlled for demographic factors and subgroup analysis excluding patients with
diabetes allowed us to address potential HCC risk factors that can be changed.
With an aging population experiencing a worsening obesity epidemic in a postDAA era, HCC risk persists and is perhaps more insidious in the absence of frank chronic
viral infection. In all patients of the Birth Cohort, the presence of diabetes, excessive
drinking, and increased BMI are associated with greater risk of HCC. In patients without
diabetes, morbid obesity (BMI >35 kg/m2) had an even greater magnitude of HCC risk
across all levels of FIB-4 stratification. The outsized effect of advanced liver disease in
previous studies may have led to an underestimation of the importance of targeting
modifiable behaviors. Our findings suggest that lifestyle modifications enacted prior to
the onset of advanced fibrosis, including improved diabetes control, smoking and alcohol
cessation, and weight loss, may greatly mitigate HCC risk.
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Chapter V: Lessons Learned from Conducting a Private Database Analysis
5.1 Epidemiology Insights
The power of conducting a quality study starts with a clearly defined research
question to allow for greater precision and validity.89 This dive into basic epidemiology
gave me an appreciation of the rigorous work needed to create quality studies. A public
access database has all factors readily available for quick investigation, but is limited to a
preset list of variables for study. Building a database from scratch requires forethough
and careful revisions - a single change in age range cutoffs or accounting for missing
variables necessitates that the entire analysis be recoded and repeated. The final work,
though entirely performed from computers, still requires hundreds of hours and
collaboration amongst experts in the field: hepatologists to help decide on clinically
relevant lab values, epidemiologists to define what studies are worth pursuing, and
statisticians to determine how to best approach the data. This second study showed me
how the wealth of electronic health data from the VA is a valuable resource to conduct
large general population studies with specified variables of interest that may not be
available in public databases, such as alcohol screening surveys. I also learned how to
carefully curate data to assess for multiple risks on a single outcome of interest – in our
case, multiple modifiable patient factors like weight, drinking, and smoking status can
affect liver cancer risk in a population.
Learning the language of statistics was also valuable and has allowed me to more
critically appraise the wealth of new studies being produced. There is a positive
publication bias, for which public databases can be datamined and important research
questions ignored or undervalued if they yield negative results.90 Lack of statistical
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significance could either mean the study was underpowered to capture a difference, or
that there was no difference in outcomes. When there are statistically significant results,
they must be interpreted through the correct clinical lens in order to draw conclusions.
Our study did not find evidence of weekend effect for hospitalizations of severe acute
liver injury – a negative result that should be seen as a positive reflection on how this
patient population has the same outcomes, regardless of admission day. There is also a
difference in interpretations of commonly used measures of association in preventative
medicine. Odds ratios can be mistakenly equated as relative risk ratios, which can lead to
inaccuracies in public health research.91 In our NIS study, we were careful to report our
findings as odds ratios and analyze the distribution of our sample to use the correct
comparison studies for significance. In our VA Birth Cohort study, we computed
univariate analyses to look for trends that would help inform the building of our
multivariate model, and reported each step in the analysis for transparency.
Even the presentation of data and language can affect the reporting of results.
The spacing, wording, shading, content of data table presentation can be used to promote
accurate communication in science, or may bury important findings and cloud the story.92
The preparation of tables and figures generated in these studies were crucial tools in our
analysis, generation of results, and the foundation of our scientific narrative. Therefore,
the mentorship of multiple experts across the disciplines of hepatology, clinical research,
epidemiology, and biostatistics was necessary for developing the clinical hypothesisdriven reasoning, analysis, results, and communication.
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5.2 Reflection
Etiologies of liver disease are actively changing in the setting of increased
exposures to hepatotoxins like acetaminophen and alcohol in acute injury, and the
worsening obesity epidemic with long-term lifestyle risk factors like smoking and alcohol
use in the setting of chronic liver injury. Even in an era with pharmacological prevention
or cure for viral hepatitis, acute and chronic liver disease risk with progression to
NAFLD, NASH, and liver cancer are on the rise. Providers have a responsibility to
educate patients on the ever-increasing importance of lifestyle behaviors, and the impact
of obesity in order to mitigate liver disease. Researchers have the opportunity to
investigate large trends in these patient populations to identify risk factors and changes in
the profile of metabolic syndrome as a public health crisis, and to inform the public of
barriers to health. By combining these disciplines, we now have a valuable opportunity to
change the landscape of liver disease. Through greater collaborative efforts to study
clinical questions in patient-centered care, we can potentially identify major trends,
inform clinical practice, and address barriers or disparities in outcomes to promote better
liver health – and ultimately quality of life – for all.
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